KISQALI 200 mg, comprimé pelliculé

( ARTG ) Early breast cancer KISQALI in combination with an aromatase inhibitor is indicated for the adjuvant treatment of patients with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HE‍‍‍‍‍‍​​​‍​​​​​​R2)-negative stage II and III early breast cancer at high risk of recurrence.,Advanced or metastatic breast cancer KISQALI is indicated for the treatment of patients with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative advanced or metastatic breast cancer, in combination with an aromatase inhibitor or fulvestrant, as initial endocrine-based therapy or following prior endocrine therapy.